COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 9 FDA records to the applicant name C.R. Bard, Inc.. The collection includes 3 510(k) clearances. It includes 1 original PMA approval. 4 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Oct 24, 1980 to Sep 29, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LMF appears in 3 of the 9 linked filings. The collection spans 6 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P800002, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 160 New Boston St., Woburn, MA, 01801. Recorded on P800002/S036, decision dated Sep 29, 2026.
Device categories in this collection
Agent, Absorbable Hemostatic, Collagen Based; Tubes, Gastrointestinal (And Accessories); System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment; Tray, Catheterization, Sterile Urethral, With Or Without Catheter (Kit); Powered Laser Surgical Instrument; Catheter, Urological.
Changes described in PMA records
The FDA recorded decision OK30 on 2026-09-29 for PMA supplement P800002/S036, submitted by C.R. Bard, Inc. as a 30-Day Notice. The supplement covers a modification of manufacturing equipment for Avitene Microfibrillar Collagen Hemostat (MCH) Non-Woven Web production. The underlying device is an absorbable, collagen-based hemostatic agent (product code LMF) associated with general and plastic surgery.
The recorded reason is a process change affecting manufacturer, sterilizer, packager or supplier. The source does not identify which equipment changed, what the modification was, or which manufacturing site is involved, and it provides no documents. The decision therefore concerns the equipment change described in the notice, not a new approval of the Avitene MCH Non-Woven Web system as a whole. No clinical or performance conclusions follow from this record.
FDA approval-order wording
modification of manufacturing equipment for Avitene MCH Non-Woven Web production
Sep 29, 2026 · 30-Day NoticeFDA’s recorded scope: updated water system equipment for the Woburn, MA manufacturing site
Jul 15, 2026 · 30-Day NoticeFDA’s recorded scope: changes to the packaging supplier's adhesive coating
Jun 10, 2026 · 30-Day NoticeFDA’s recorded scope: changes to the stent electropolishing and final stent cleaning processes
Dec 16, 2025 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.